What is a stock summary page? Click here for an overview.
Business Description
Sutro Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US8693671021
Compare
Compare
Traded in other countries / regions
STRO.USAS09.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2018-09-27Description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.69 | |||||
| Equity-to-Asset | 0.12 | |||||
| Debt-to-Equity | 0.52 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -3.56 | |||||
| Beneish M-Score | -3.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.6 | |||||
| 3-Year EBITDA Growth Rate | -4.8 | |||||
| 3-Year EPS without NRI Growth Rate | -10.5 | |||||
| 3-Year FCF Growth Rate | -6.4 | |||||
| 3-Year Book Growth Rate | -53.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 25.84 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.8 | |||||
| 9-Day RSI | 22.71 | |||||
| 14-Day RSI | 24.53 | |||||
| 3-1 Month Momentum % | -26.41 | |||||
| 6-1 Month Momentum % | -59.35 | |||||
| 12-1 Month Momentum % | -71.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.6 | |||||
| Quick Ratio | 2.6 | |||||
| Cash Ratio | 2.4 | |||||
| Days Sales Outstanding | 105.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.2 | |||||
| Shareholder Yield % | -168.34 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -384.34 | |||||
| Net Margin % | -366.62 | |||||
| FCF Margin % | -313.71 | |||||
| ROE % | -204.67 | |||||
| ROA % | -51.64 | |||||
| ROIC % | -198.84 | |||||
| 3-Year ROIIC % | 1172.87 | |||||
| ROC (Joel Greenblatt) % | -473.68 | |||||
| ROCE % | -58.09 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.75 | |||||
| PB Ratio | 1.1 | |||||
| Price-to-Tangible-Book | 1.1 | |||||
| EV-to-EBIT | 1.27 | |||||
| EV-to-EBITDA | 1.32 | |||||
| EV-to-Revenue | -3.88 | |||||
| EV-to-Forward-Revenue | 0.08 | |||||
| EV-to-FCF | 1.24 | |||||
| Price-to-GF-Value | 0.23 | |||||
| Price-to-Net-Current-Asset-Value | 59.25 | |||||
| Earnings Yield (Greenblatt) % | 78.74 | |||||
| FCF Yield % | -392.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:STRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sutro Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 62.043 | ||
| EPS (TTM) ($) | -3.02 | ||
| Beta | 1.4 | ||
| 3-Year Sharpe Ratio | -0.44 | ||
| 3-Year Sortino Ratio | -0.61 | ||
| Volatility % | 96.46 | ||
| 14-Day RSI | 24.53 | ||
| 14-Day ATR ($) | 0.111787 | ||
| 20-Day SMA ($) | 0.94257 | ||
| 12-1 Month Momentum % | -71.81 | ||
| 52-Week Range ($) | 0.5633 - 5.275 | ||
| Shares Outstanding (Mil) | 83.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sutro Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sutro Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sutro Biopharma Inc Frequently Asked Questions
What is Sutro Biopharma Inc(STRO)'s stock price today?
The current price of STRO is $0.59. The 52 week high of STRO is $5.28 and 52 week low is $0.56.
When is next earnings date of Sutro Biopharma Inc(STRO)?
The next earnings date of Sutro Biopharma Inc(STRO) is 2025-05-13 Est..
Does Sutro Biopharma Inc(STRO) pay dividends? If so, how much?
Sutro Biopharma Inc(STRO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers